文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤放疗物理与技术

前列腺癌寡转移SABR后PSMA-PET/CT的长期疗效评估

PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-07-23

该回顾性单中心分析纳入48例接受PSMA-PET/CT引导SABR(5×7 Gy)的寡转移性前列腺癌患者,共97个照射病灶和145次PSMA-PET/CT扫描。首次随访中位13个月时病灶中位SUVmax从10.88降至2.2,49个病灶达完全缓解,5年局部控制率86%,未见急慢性毒性。

要点

  • PSMA-PET/CT引导SABR后5年局部控制率达86%,耐受性良好。
  • 首次随访中位13个月时49/97个病灶达完全缓解,中位SUVmax由10.88降至2.2。
  • 随访期间最多90%病灶出现完全缓解,中位达SUVmin时间为19个月。

核心结论

  • PSMA-PET/CT引导的SABR对寡转移性前列腺癌的骨和淋巴结转移提供良好的长期局部肿瘤控制,且耐受性良好。
  • 初始复查PSMA-PET/CT后PSMA活性可能进一步下降。

研究设计与样本

  • 回顾性单中心分析纳入2015至2019年间接受PSMA-PET/CT引导SABR(5×7 Gy)且至少有一个骨或淋巴结病灶的初发寡转移或寡进展前列腺癌患者,并要求有一次以上随访PSMA-PET/CT。
  • 共分析48例患者、97个照射病灶和145次PSMA-PET/CT扫描;26例患者曾接受雄激素剥夺治疗(ADT)。
  • PSMA反应通过视觉和定量评估SABR前后局部PSMA摄取进行判定。

主要发现

  • SABR前病灶中位SUVmax为10.88(范围1.59-122.11),中位CTV为4.75 cm3(范围0.68-60.4 cm3)。
  • SABR后中位13个月(范围3-42)的首次随访PET/CT中,病灶中位SUVmax降至2.2(范围0.13-26.09)。
  • 首次随访时49个病灶达完全缓解,32个部分缓解,12个稳定,4个无反应。
  • 随访至多5次PSMA-PET/CT期间,最多90%的病灶出现完全缓解;中位达SUVmin时间为19个月(范围3-50)。
  • 5年局部控制率为86%,未报告短期或长期毒性。

临床怎么用

  • PSMA-PET/CT引导SABR可作为寡转移性前列腺癌骨和淋巴结转移的有效局部治疗选择,局部控制持久且安全性好。
  • 随访中PSMA-PET/CT的定量SUVmax变化可辅助评估局部治疗反应,但需注意反应可能延迟,初始复查后PSMA活性仍可能进一步下降。

局限性

  • 回顾性单中心设计,样本量有限(48例患者、97个病灶)。
  • 部分患者接受ADT,可能影响PSMA摄取与反应评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: PSMA-PET/CT is frequently used for staging patients with de-novo or recurrent prostate cancer (PCa). In patients with oligometastatic PCa PSMA-PET/CT guided stereotactic ablative body radiotherapy (SABR) is a common treatment option. Follow-up is regularly performed via measurement of prostate-specific-antigen (PSA) level. Response assessment based on follow-up PSMA-PET/CTs is poorly studied. Therefore, we report on long-term local tumor response using repeated PSMA-PET/CTs of patients with oligometastatic PCa after PSMA-PET/CT guided SABR. METHODS/PATIENTS: Patients with de-novo oligometastatic or oligoprogressive PCa who received PSMA-PET/CT-directed SABR with 5 × 7 Gy of at least one bone or lymph node lesion between 2015 and 2019 and had one or more follow-up PSMA-PET/CT were included in this retrospective single center analysis. PSMA response was evaluated by visual and quantitative assessment of local PSMA uptake pre- and post-SABR. RESULTS: Overall, 48 patients with 97 irradiated lesions and a total of 145 PSMA-PET/CT-scans were analyzed. 26 patients received androgen-deprivation-therapy (ADT) at any time. Median SUVmax per lesion was 10.88 (range 1.59-122.11) before SABR with a median CTV of 4.75 cm3 (Range 0.68-60.4 cm3). In the first follow-up PET/CT after a median of 13 months (range 3-42) after SABR, median SUVmax per lesion declined to 2.2 (range 0.13-26.09). Complete remission (CR) was observed in 49 lesions, partial remission in 32 and stable disease in 12 lesions. Four lesions were non-responders. Over the course of up to five follow-up PSMA-PET/CTs a maximum of 90 % of the lesions showed CR. Median time to SUVmin was 19 months (range 3-50). 5-year local control was 86 %. No short-term or long-term toxicities were reported. CONCLUSION: PSMA-PET/CT directed SABR provides excellent long-term local tumor control of 90% in bone and lymph node metastasis of oligometastatic PCa and is well tolerated. PSMA activity may further decrease after initial re-imaging with PSMA-PET/CT.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zang AL, Maier T, Freitag-Wolf S, et al. PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer. Clin Transl Radiat Oncol. 2025. PMID: 40778088. doi:10.1016/j.ctro.2025.101021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。